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ABSTRACT
Objective: To estimate the placebo and nocebo responses in restless legs syndrome (RLS) and
explore their determinants.
Methods: Databases were searched up to October 2015. Randomized, double-blind, placebo-
controlled trials of patients with RLS were included if quantitative data were extractable in the
placebo arm. Placebo response was defined as the within-group change from baseline, using
any scale measuring RLS severity or disability. Nocebo response was defined as the proportion
of patients experiencing adverse events in the placebo arm. Random-effects meta-analysis was
used to pool data. Statistical heterogeneity was assessed with I2 statistic. Several predetermined
subgroup and sensitivity analysis were performed. PROSPERO registration number is
CRD42015027992.
Results: We included 85 randomized controlled trials (5,046 participants). Pooled placebo
response effect size was 21.41 (95% confidence interval [CI] 21.56 to 21.25, 64 trials, I2 5
88.1%), corresponding to 26.58 points in the International RLS Study Group Scale (IRLS).
Pooled nocebo response was 45.36% (95% CI 40.47%–50.29%, 72 trials; I2 5 89.8%). The
placebo and nocebo responses were greater in trials with longer duration, evaluating pharmaco-
logic interventions and idiopathic RLS, and in industry-funded and unpublished studies. The pla-
cebo response was considerably smaller in objective as compared to subjective outcomes. In
addition, the nocebo response increases proportionally with the placebo response, and has the
same predictors.
Conclusions: The magnitude of the placebo response in RLS is above the threshold of minimal
clinical important difference, and the frequency of adverse events is also considerable. These
results are relevant to inform the design and interpretation of future clinical trials. Neurology®
2017;88:1–9
GLOSSARY
CGI5Clinical Global Impression improvement scale; CI5 confidence interval; ES5 effect size; IRLSSG5 International RLS
Study Group; MCID 5 minimal clinically important difference; PGI 5 Patient Global Impression improvement scale; PLM 5
periodic limb movements; PLMI 5 periodic limb movements index; PLMSI 5 periodic limb movements of sleep index; RCT 5
randomized controlled trial; RLS 5 restless legs syndrome.
Restless legs syndrome (RLS) is a chronic neurologic disorder1 with negative effects on quality of
life and sleep of patients and bed partners. RLS prevalence may reach up to 10% of the
population.2 The pathophysiology of RLS is not completely understood, and multiple abnormal
processes in the central and peripheral nervous systems have been empirically studied. Further-
more, there seems to be a strong genetic susceptibility in affected patients.3
In addition to responses to opioid agents, and both dopaminergic and a-2-d ligands, numer-
ous trials have reported considerable improvements under placebo treament.4
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The key assumption regarding placebo, and
the reason why we use it in clinical trials, is that
it has no biological activity of interest. There-
fore, any improvement seen in patients taking
a placebo is deemed to result from the positive
expectation of receiving an intervention. Since
the work of Beecher,5 a new line of research
has emerged that brought the response to pla-
cebo to the forefront of interventional research.
Thus, we hypothesize that the placebo
effect in RLS is relevant for trials’ design and
clinical interpretation of the findings, set out
to quantify the magnitude of placebo and no-
cebo responses in RLS, and explore their
determinants.
METHODS Standard protocol approvals and registra-
tions. We report this systematic review and meta-analysis ac-
cording to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidelines.6 The protocol was prospectively
registered with PROSPERO (registration: CRD42015027992).
Eligibility criteria. We included double-blind randomized
controlled trials (RCTs) with parallel or crossover design and at
least one active treatment arm and a placebo arm. We excluded
trials with an active run-in period before intervention with pla-
cebo. Patients required a diagnosis of RLS according to the
International RLS Study Group (IRLSSG) criteria1,7 or another
specified method, if the study was conducted before the IRLSSG
criteria publication. Studies were accepted regardless of RLS eti-
ology, comorbid conditions, or age. We accepted any interven-
tion categorized as placebo. Studies had to report quantitative
data on at least one of the following outcomes, measured by
validated instruments, within the placebo arm:
Primary efficacy outcome. The primary efficacy outcome
was placebo response, defined as the within-group change from
baseline, using any rating scale measuring RLS severity or
disability.
Primary safety outcome. The primary safety outcome was
nocebo response, defined as the proportion of patients experienc-
ing adverse events in the placebo arm.
Secondary efficacy outcomes. The secondary efficacy out-
comes were change from baseline in the following endpoints:
Clinical and Patient Global Impression improvement scales
(CGI and PGI, respectively), quality of life, self-rated quality of
sleep, daytime somnolence, sleep efficiency, and number of
periodic limb movements (PLM) per hour of sleep or of time in
bed (PLM of sleep index [PLMSI] and PLM index [PLMI],
respectively). CGI, PGI, quality of life, self-rated quality of sleep,
daytime somnolence, and sleep efficiency are subjective out-
comes, while PLMSI and PLMI represent objective outcomes.
Secondary safety outcomes. The secondary safety outcomes
were proportion of withdrawals due to adverse events and propor-
tion of patients experiencing augmentation, defined as “worsen-
ing of RLS symptoms, attributable to a specific therapeutic
intervention for RLS.”1 For proposes of inclusiveness, other def-
initions were accepted.
No language, year of publication, or publication status restric-
tions were applied.
Information sources. We searchedMEDLINE, EMBASE, and
the Cochrane Register of Controlled Trials (CENTRAL) data-
bases from inception to October 2015. Clinical trial registries
(WHO International Clinical Trials Registry Platform and
Clinicaltrials.gov) were also searched. Reference lists were cross-
checked for additional citations.
Search. The search strategy combined variations of terms related
to placebo and RLS. The Cochrane Highly Sensitive Search
Strategy for identifying RCTs (2008 revision) was used for
MEDLINE.8 The search was restricted to human studies. All
terms were searched as free text and controlled vocabulary. The
complete search strategy for MEDLINE can be found in appen-
dix e-1 at Neurology.org.
Study selection. Two reviewers independently screened titles
and abstracts and analyzed full-text reports for potential inclu-
sion. Disagreements were solved by consensus or by an inde-
pendent party.
Data collection process. Two reviewers independently ex-
tracted individual study data onto a piloted form.
Risk of bias in individual studies. We used the Cochrane risk
of bias tool to classify studies as being at low, high, or unclear risk
of bias in the following domains: randomization, allocation con-
cealment, blinding of participants and personnel, blinding of out-
come assessment, incomplete outcome data, and selective
reporting.8 Other sources of bias were considered, including
funding, exclusive inclusion of special or enriched populations,
and carryover effect in crossover trials. Two authors indepen-
dently assessed risk of bias. Disagreements were solved by con-
sensus or by a third party.
Summary measures. The placebo and nocebo data were
derived from the last measured within-group response in the
placebo arms of RCTs. Whenever possible, we retrieved and
analyzed intention-to-treat data. The effect measure for con-
tinuous outcomes was effect size (ES). The ES was calculated as
the quotient of the mean change from baseline divided by the
SD at baseline, correcting for small-sample bias.9 Negative
changes indicate improvement in RLS severity, daytime som-
nolence, PLMSI, and PLMI, while positive differences indicate
benefit in sleep quality, quality of life, and sleep efficiency. In
case of insufficient reported data, we contacted authors as a first
approach. In the lack of a positive response, absent mean
changes from baseline and SDs were extracted from unpub-
lished material. In some trials, SD was obtained from standard
error or confidence intervals (CI). When such values were not
reported, imputation methods were applied as described in
appendix e-2. We also performed the analyses with the mean
change from baseline and SD, using the natural units of the
most commonly applied scale for each outcome. When a dif-
ferent scale was used, linear rescaling to the chosen instrument
was conducted.10 Dichotomous outcomes are reported as pro-
portions. Heterogeneity between trial results was tested using
a standard x2 test and I2 statistic was calculated for quantifying
this inconsistency. We presented all results with 95% CI.
Additional analyses. The following predefined subgroup analy-
ses were conducted to explore heterogeneity: time to last assessment
(less than 6 weeks, 6–11 weeks, and 12 or more weeks), study
intervention (pharmacologic vs nonpharmacologic intervention,
route of administration of pharmacologic interventions), study pop-
ulation (idiopathic vs secondary RLS, naive vs previously treated
patients), and published vs unpublished trials. In addition, to assess
the influence of study quality on results, subgroup analyses of
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studies with a low risk of bias vs those with unclear/high risk were
performed. Predefined sensitivity analyses were conducted exclud-
ing studies where imputation methods were applied, and studies
with crossover designs. The subgroup and sensitivity analyses were
performed exclusively for the primary outcomes. Meta-regressions
were performed for the primary efficacy outcome according to year
of publication and to disease severity at baseline.11
Taking into consideration the findings of our meta-analysis
regarding the pooled magnitude of the placebo response, we then
performed sample size calculations for a hypothetical future
equivalence trial that would be powered to detect differences
in IRLS from placebo group of 5%, 10%, 15%, and 20% using
a5 0.05 and b5 0.1, in the R software.12 Finally, we conducted
a post hoc Pearson correlation analysis to investigate the relation
between the placebo (primary efficacy effect) and the nocebo
responses (primary safety effect), after establishing the normality
of the data with a Shapiro-Francia W9 test for normal data.
RESULTS Study selection and characteristics. We
included 85 RCTs (5,046 participants) (figure e-1),
65 with a parallel design, 5 tested nonpharmacologic
procedures, and the remaining were pharmacologic tri-
als, 65 of which with oral interventions. The most
commonly studied drugs were ropinirole (n 5 13),
pramipexole (n 5 12), rotigotine (n 5 10), and
gabapentin-enacarbil (n 5 10). Five were performed
exclusively in RLS secondary to end-stage renal disease
under hemodialysis, and 70 exclusively enrolled pa-
tients with idiopathic RLS. Overall, the average age
was 54.21 years, and 62.24% of patients were female.
The mean IRLS score at baseline was 24.51 points. See
table e-1 for characteristics of included studies and
appendix e-3 for study references.
Risk of bias within studies. Twenty-five studies were
deemed as having a low overall risk of bias (figure 1).
The detailed risk of bias across studies can be found in
figure e-2.
Synthesis of results and additional analysis. Primary effi-
cacy outcome: Placebo response. Sixty-four studies re-
ported a validated RLS severity assessment included
in the primary efficacy outcome analysis, 62 of which
used the IRLS. Among studies that did not use the
IRLS, 2 used severity assessments that were eligible
for inclusion and rescaled. The pooled ES was
21.41 (95% CI 21.56 to 21.25; figure 2), corre-
sponding to a mean IRLS reduction of 6.58 points
(95% CI 4.86–8.29). Statistical heterogeneity was
very high (I2 5 88.1%).
Subgroup analysis revealed a greater improvement
with placebo in studies with 12 or more weeks, stud-
ies with pharmacologic interventions, RCTs per-
formed in idiopathic RLS, unpublished trials, and
industry-supported studies (table e-2). Subgroup
analyses of oral vs nonoral medications and low vs
high/unclear overall and specific domain risk of bias
did not reveal differences between groups.
No differences were observed in sensitivity analyses
(table e-2) or in metaregressions for disease severity at
baseline (b 5 20.05; 95% CI 20.12 to 0.01) and
year of publication (b 5 20.04; 95% CI 20.09 to
0.01; figures e-3 and e-4, respectively). The predefined
subgroup and sensitivity analyses were not able to ade-
quately explain the considerable statistical heterogene-
ity we found (table e-2).
Primary safety outcome: Nocebo response. Overall,
45.36% (95% CI 40.47%–50.29%, 72 trials; I2 5
89.8%) of patients experienced adverse events (figure
3). The proportion of patients experiencing any
Figure 1 Risk of bias across domains
Each methodologic quality item is presented as percentages across included studies.
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adverse events was greater in studies of 12 or more
weeks, in pharmacologic studies, in idiopathic RLS,
in unpublished trials, and in industry-funded trials
(table e-2). Statistical heterogeneity was not explained
by the predefined subgroup and sensitivity analysis
(table e-2).
Figure 2 Change from baseline in restless legs syndrome severity under placebo
CI 5 confidence interval; ES 5 effect size.
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Secondary efficacy outcomes. Seventeen studies re-
ported both CGI and PGI; 24 only reported GCI
and 3 others applied PGI. Overall, 45.46% of clini-
cians and 40.00% of patients reported a much
improved or very much improved response under
placebo (figure 4). Twenty-one studies reported
quality of life assessments in an extractable manner,
with overall quality of life improving under placebo
(figure 4).
Thirty-one studies addressed daytime somno-
lence, having documented a reduction in daytime
somnolence associated with placebo (figure 4).
Quality of sleep was rated in 35 studies. A signif-
icant improvement was found (figure 4).
Sleep efficiency, defined as the proportion of total
sleep time during time in bed, was reported in 16
studies. PLMSI was reported in 14 studies and PLMI
in 12 studies. Pooled ES for sleep efficiency was
Figure 3 Adverse events rate under placebo
CI 5 confidence interval; ES 5 effect size.
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nonsignificant (figure 4). Regarding PLM, an
improvement was observed in PLMI, but not in
PLMSI (figure 4).
Secondary safety outcomes. A total of 208 (2.07%)
withdrawals occurred due to adverse events in the pla-
cebo arm, among 81 studies (4,797 participants).
Twenty-two studies reported augmentation in 13 of
1,863 participants, with no information from re-
maining trials.
Sample size calculation. Table e-3 shows the esti-
mated sample size required in an adequately powered
future trial (a5 0.05;b5 0.10) to detect a difference
between treatment arms of 5%, 10%, 15%, and 15%
in the IRLS, taking into consideration that on average
patients under placebo treatment have an improve-
ment of 6.58 points.
Correlation analysis. The placebo and nocebo
response were reported concomitantly in 46 RCT.
The nocebo response increases proportionally with the
placebo response (r 5 0.45, p 5 0.0005; figure 5).
DISCUSSION This systematic review and meta-
analysis demonstrated a large response to placebo in
RLS, with an average mean reduction in IRLS of 6.58
points. We additionally documented that many
placebo-treated participants have adverse events
(45.36%)—the nocebo response, and these responses
change proportionally to one another.
Subgroup analyses showed that the placebo and
nocebo responses vary in unison: both were increased
in longer studies, in studies evaluating pharmacologic
interventions and idiopathic forms of RLS, in
industry-funded trials, and in unpublished trials.
All continuous self-rated outcomes (quality of life,
sleep quality, and daytime somnolence) improved
with placebo. However, the placebo response was
small to nonexistent for objective outcomes (PLMI
and PLMSI).
These findings imply that although people with
RLS report considerable improvement with placebo,
even in the most common clinical scale in usage—
the IRLS—this is not accompanied by an actual
improvement in the limb movements that more pre-
cisely characterize and define the condition.
Our findings are in accordance with a previous
systematic review in RLS4 that included a smaller
number of trials (n 5 36) and participants (n 5
1,748), documenting substantial placebo responses
in subjective outcomes, more evident in longer trials.
The pattern is consistent with research in other
areas,13 such as in major depressive disorder,14 though
not, for example, in the case of Parkinson disease.15 In
contrast, an analysis of the predictors of placebo
response in 6 RCTs, enrolling 883 participants, re-
vealed greater placebo responses in more severe cases,
and did not find differences concerning study
duration.16
Our review quantified the change under placebo
across several RLS outcomes, most of them showing
improvement with placebo treatment. Two questions
emerge: are those changes clinically relevant? Do they
reflect a placebo effect?
For RLS severity, the first question could be
answered when considering the minimal clinically
important difference (MCID) for IRLS, i.e., the
smallest change that patients perceive as important,
using IRLS. Despite the absence of a consensual
MCID for this scale, post hoc analyses of 2 trials
included in this review17,18 obtained a MCID of 519
and 620 points in IRLS. In addition, 15 of the 21
studies that used a MCID (used for sample size cal-
culations in included trials) used a lower value than
Figure 4 Change from baseline under placebo in secondary efficacy outcomes
Negative effect size (ES) changes indicate improvement in daytime somnolence, periodic
limb movements of sleep index (PLMSI), and periodic limb movements index (PLMI), while
positive differences illustrate benefit in Clinical Global Impression improvement scales
(CGI), Patient Global Impression improvement scales (PGI), quality of sleep, quality of life,
and sleep efficiency. CI 5 confidence interval.
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the 6.58 points we found for our sample size calcu-
lations. The mean of minimal changes across these
studies was 5.6 points. Thus, we can state that the
placebo response found in this review exceeded the
threshold for the MCID.
The answer to the second question is more com-
plex, since we cannot identify to what extent our
findings were affected by the natural course of
RLS. Research evaluating placebo vs no treatment
control groups in clinical trials, regardless of the
condition, did not find that placebo interventions
have clinically meaningful effects when compared
with no treatment.21 Only by including both no
treatment and placebo arms in RCTs could we
assess if our findings are indeed due to the placebo
effect and not related to the natural course of the
illness, patient–doctor relationship, or the expecta-
tion of being involved in a clinical trial, among
many possible reasons.
In general, RLS is known to respond to dopami-
nergic stimuli.17 Interestingly, studies in pain and
Parkinson disease have shown that the placebo
response maybe mediated by dopamine.22,23 This
could partially explain the magnitude of our results.
That being said, there is also evidence of equally great
responses where dopamine is not a major player, such
as depression.14
In addition, dopamine plays a role in the brain
reward systems and conditioning.24 A certain number
of participants included in our analysis may have been
previously conditioned by an exposure to an
efficacious intervention, and placebo interventions
could have triggered some of these systems.
To our knowledge, our work is the largest sys-
tematic review evaluating the placebo response in
RLS and the only one characterizing the nocebo
response.
Our comprehensive search of the available evi-
dence, using a far-reaching strategy and including
clinical trial registries, allowed the inclusion of
both published and unpublished RCTs. Four refer-
ences generated by the search could not be
retrieved12,25–27 though these are unlikely to report
a validated RLS severity assessment, having been
published before IRLS validation. We assume these
studies would not appreciably influence our pri-
mary outcomes.
Despite of the all-inclusiveness of our study, cer-
tain relevant data were generally not reported. Most
included RCTs did not report separated results for
naive and previously treated patients. An analysis of
2 RCTs found that pretreatment for RLS was associ-
ated with a smaller placebo response, in comparison
to naive patients.28 The authors postulate that pre-
vious treatment may contribute to conscious or
unconscious unblinding of participants. Owing to
insufficient reporting, we could not study this via
a subgroup analysis, and therefore cannot corroborate
such results.
Another field lacking data is RLS in children. On-
ly one small trial could be included and it had the
confounding factor of only including patients with
attention-deficit/hyperactivity disorder, often mis-
diagnosed in children with RLS.29
As secondary RLS was an exclusion criterion in
most of the included trials, this population was insuf-
ficiently addressed. Uremic RLS was notable for
being poorly studied, as only 5 small trials (enrolling
62 participants overall) were included, meaning that
extrapolation to this population should be done with
care. We found no trials studying pregnant women
with RLS or people with iron-deficient anemia.
Finally, few of the included studies reported aug-
mentation (22 RCTs). Typically augmentation is re-
garded as a complication of long-term treatment,
though it may occur at any time.1 Underreporting
may relate to selective reporting bias, and diminishes
the quality of the evidence.
Regarding methodologic quality, many of the
included studies had a risk of both selection and
detection bias, and were at high risks of reporting
bias, mainly for not reporting reasons for study dis-
continuation and incomplete data description, pre-
cluding the inclusion of one or more outcomes for
analysis.
When contacting authors, we did not request data
regarding naive/previously treated participants or
Figure 5 Correlation between the placebo and the nocebo response
The placebo response corresponds to the within-group change from baseline, using any rat-
ing scale measuring RLS severity or disability, and the nocebo response to the proportion of
patients experiencing adverse events in the placebo arm. For the sake of interpretability, the
placebo response scale was inverted. r, Pearson coefficient of correlation; p, p value.
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methodologic characteristics. Despite studying the
nocebo response, we only accounted for global
adverse events rates, regardless of their nature and
of being intervention-related or not.
We performed sensitivity analyses for the primary
efficacy outcome considering potential sources of
bias. Pooling data from both phases of crossover trials
could potentially be an issue,8 though sensitivity anal-
ysis suggests it was not in our case. Similarly, impu-
tation methods had no effect on our results.
The magnitudes of the placebo and nocebo re-
sponses in RLS are substantial, show similar patterns
of variation, and change proportionally to one
another. Indeed, the placebo response exceeds the
threshold for clinical relevance, which is of great per-
tinence for planning future trials.
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